Innate Pharma announces results from TELLOMAK study

Innate Pharma announced results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides, or MF. The results were presented at the ASCO 2024 annual meeting, in Chicago, Illinois. As of October 13, 2023, data cutoff, MF patients received a median of four prior systemic therapies and had a median follow-up of 11.8 months. The data demonstrate that treatment with lacutamab resulted in meaningful antitumor activity, regardless of the KIR3DL2 baseline expression, and an overall favorable safety profile. The global objective response rate, or ORR, was 16.8% and 22.4%, including 2 complete responses and 16 partial responses. In patients expressing a baseline KIR3DL2 of 1%, the ORR was 20.8% and 29.2%. Median progression-free survival was 10.2 months for all MF patients and 12 months in the KIR3DL2 1% group. Time to response was one month.